Drug approval requires demonstrated efficacy plus safety
The decision to stop tirzepatide should always involve shared decision-making with your healthcare provider, considering individual circumstances, treatment goals, and the availability of alternative management strategies
Failure-Tolerant Funding Create grant categories where "negative" results are valued equally with positive ones
And our current thinking about obesity, and one of the components of the disease of obesity, is that some individuals although they all have GLP-1 and these other gut hormones, amylin, glucagon, GIP, that's what they're called that signal, for some reason, is not getting to the brain in ample amounts to tell the individual to feel full, satiated, and stop eating
During the Q&A session, Frias was asked whether he was surprised about the safety profile from the trial, as no participants in the combination group withdrew due to adverse events
Explore the impact of rising GLP-1 costs on employer health benefits